Company insight
with high prevalence of AMR, and showed that ASTar had a strong overall agreement with reference BMD methods in E. coli isolates harbouring blaOXA-1
and blaTEM-1 .
Resistance genes associated with poor reliability in piperacillin-tazobactam (PTZ) AST from commercial panels that frequently yield MIC values within the area of technical uncertainty category (ATU), possibly contributing to increased mortality. Because of this, several guidelines have recently rejected the use of PTZ as a carbapenem-sparing agent in ESBL- producing infections.
The fully automated ASTar system shortens the clinical workfl ow and enables predictable turnaround times.
AST run, without the need for follow-up testing. Earlier initiation of optimal therapy is crucial for better long-term outcomes. Survivors often grapple with a life-altering aftermath that could be mitigated by more responsive interventions that reduce the risk of morbidities associated with suboptimal therapies and long hospital stays.
ASTar publications
In an era where rising rates of AMR are making it increasingly more complicated to treat patients successfully, Q-linea believes ASTar is well equipped to aid in the management of BSIs in even the most challenging cases. This has been reflected in several ASTar performance studies.
study. Here, Q-linea demonstrated the high accuracy and consistent reproducibility of ASTar when compared with broth microdilution (BMD) for a wide range of fastidious and non-fastidious bacteria and a broad range of antibiotics including ceftalozane/tazobactam and ceftazidime/ avibactam, as well as colistin, a ‘last-resort’ antibiotic. Q-linea was pleased to prove that ASTar is already well prepared to empower clinicians to optimally manage BSIs caused by a breadth of pathogens, facilitated by a broad drug panel that has the potential for future expansion with novel antibiotics. An evaluation conducted in Whiston, UK, showed the enormous difference ASTar can make during routine testing when
“In an era where rising rates of AMR are making it increasingly more complicated to treat patients successfully, Q-linea believes ASTar is well equipped to aid in the management of BSIs in even the most challenging cases.”
In fact, Q-linea was proud to be acknowledged for having the best clinical microbiology publication with respect to rapid AST during ASM 2023. The paper ‘Performance of a System for Rapid Phenotypic Antimicrobial Susceptibility Testing of Gram-Negative Bacteria Directly from Positive Blood Culture Bottles’, was published in the Journal of Clinical Microbiology and summarises the results of the ASTar European clinical performance
28
implemented in a 24/7 microbiology laboratory, especially in cases of resistant infections. By reducing time to optimal treatment by over 24 hours when compared with the current standard of care, ASTar prompts faster antimicrobial adjustments when time matters most and would ensure patients are more quickly placed on regimens that truly benefit them. Additionally, Q-linea carried out a retrospective study in Sevilla, Spain, a region
The study showed that ASTar can provide MIC of PTZ on the same working day as detecting an E. coli-positive blood culture, with strong concordance to reference, even in isolates that pose difficulties with other commercial devices. With this improvement in the accuracy of piperacillin/tazobactam sensitivity, this combination could be re-evaluated for use in ESBL-producing infections.
Looking to the future
At Q-linea, it has been an exciting year where the company has expanded its operations throughout Europe, securing multiple distribution partnerships in the UK, France, Norway and Poland, and formed a legal entity in Italy to accelerate the commercialisation of ASTar.
Q-linea is also gaining momentum in the US, having completed its FDA clinical trials, and begun expanding its commercial organisation there. Several ASTar evaluations and studies have been completed and others are ongoing in several geographies. It is evident that increasing AMR and the impact it has on the treatment of infectious diseases is a global issue causing millions of potentially avoidable deaths and driving up the cost of healthcare. To tackle challenges like AMR and improve the management of septic patients, rapid AST is becoming an essential component in every diagnostics lab, and the strong interest we have seen so far shows that ASTar is ideally fitted for this cause. Q-linea has confidence that the continuous refinement of the ASTar system helps to future-proof healthcare and will help to ensure that antibiotics continue to be an effective treatment option for future generations. ●
https://qlinea.com Practical Patient Care /
www.practical-patient-care.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61
